TriSalus Life Sciences, Inc. (NASDAQ: TLSI) Stock Competitors & Peer Comparison
See TLSI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TLSI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TLSI | $4.29 | -1.61% | 162.6M | -2.55 | -$1.68 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.68 | +1.87% | 175.3B | 19.32 | $5.21 | +2.48% |
| ISRG | $345.42 | -11.20% | 142.5B | 41.82 | $9.62 | N/A |
| SYK | $319.87 | -3.42% | 122.6B | 23.89 | $13.39 | +1.09% |
| MDT | $83.20 | -0.43% | 106.5B | 15.04 | $5.53 | +3.43% |
| BSX | $44.03 | -1.32% | 65.4B | 14.20 | $3.10 | N/A |
| EW | $85.73 | -2.40% | 49.4B | 31.75 | $2.70 | N/A |
| DXCM | $76.65 | -1.71% | 29.6B | 32.90 | $2.33 | N/A |
| RMD | $198.99 | -1.86% | 28.9B | 18.47 | $10.77 | +1.21% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
TLSI vs BSX-PA Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, TLSI's ROE is +1.63%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, TLSI is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
TLSI vs ABT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ABT has a market cap of 175.3B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ABT trades at $100.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ABT's P/E ratio is 19.32. In terms of profitability, TLSI's ROE is +1.63%, compared to ABT's ROE of +0.12%. Regarding short-term risk, TLSI is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ABT's competition here
Intuitive Surgical, Inc. (NASDAQ: ISRG)
TLSI vs ISRG Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ISRG has a market cap of 142.5B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ISRG trades at $345.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ISRG's P/E ratio is 41.82. In terms of profitability, TLSI's ROE is +1.63%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, TLSI is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check ISRG's competition here
Stryker Corporation (NYSE: SYK)
TLSI vs SYK Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SYK has a market cap of 122.6B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SYK trades at $319.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SYK's P/E ratio is 23.89. In terms of profitability, TLSI's ROE is +1.63%, compared to SYK's ROE of +0.15%. Regarding short-term risk, TLSI is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check SYK's competition here
Medtronic plc (NYSE: MDT)
TLSI vs MDT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, MDT has a market cap of 106.5B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while MDT trades at $83.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas MDT's P/E ratio is 15.04. In terms of profitability, TLSI's ROE is +1.63%, compared to MDT's ROE of +0.10%. Regarding short-term risk, TLSI is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
TLSI vs BSX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BSX has a market cap of 65.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BSX trades at $44.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BSX's P/E ratio is 14.20. In terms of profitability, TLSI's ROE is +1.63%, compared to BSX's ROE of +0.15%. Regarding short-term risk, TLSI is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
TLSI vs EW Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while EW trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas EW's P/E ratio is 31.75. In terms of profitability, TLSI's ROE is +1.63%, compared to EW's ROE of +0.11%. Regarding short-term risk, TLSI is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
TLSI vs DXCM Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while DXCM trades at $76.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas DXCM's P/E ratio is 32.90. In terms of profitability, TLSI's ROE is +1.63%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, TLSI is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
TLSI vs RMD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, RMD has a market cap of 28.9B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while RMD trades at $198.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas RMD's P/E ratio is 18.47. In terms of profitability, TLSI's ROE is +1.63%, compared to RMD's ROE of +0.24%. Regarding short-term risk, TLSI is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check RMD's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
TLSI vs ZBH Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ZBH trades at $91.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ZBH's P/E ratio is 10.75. In terms of profitability, TLSI's ROE is +1.63%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, TLSI is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
TLSI vs ABMD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ABMD's P/E ratio is 65.36. In terms of profitability, TLSI's ROE is +1.63%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, TLSI is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ABMD's competition here
Smith & Nephew plc (NYSE: SNN)
TLSI vs SNN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SNN trades at $30.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SNN's P/E ratio is 16.53. In terms of profitability, TLSI's ROE is +1.63%, compared to SNN's ROE of +0.12%. Regarding short-term risk, TLSI is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
TLSI vs ALGN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ALGN has a market cap of 12.7B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ALGN trades at $176.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ALGN's P/E ratio is 16.11. In terms of profitability, TLSI's ROE is +1.63%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, TLSI is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ALGN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
TLSI vs SWAV Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SWAV's P/E ratio is 78.76. In terms of profitability, TLSI's ROE is +1.63%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, TLSI is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
TLSI vs PEN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while PEN trades at $318.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas PEN's P/E ratio is 83.11. In terms of profitability, TLSI's ROE is +1.63%, compared to PEN's ROE of +0.12%. Regarding short-term risk, TLSI is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check PEN's competition here
Insulet Corp. (NASDAQ: PODD)
TLSI vs PODD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, PODD has a market cap of 11.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while PODD trades at $164.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas PODD's P/E ratio is 30.49. In terms of profitability, TLSI's ROE is +1.63%, compared to PODD's ROE of +0.21%. Regarding short-term risk, TLSI is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
TLSI vs GMED Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, GMED has a market cap of 10.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while GMED trades at $77.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas GMED's P/E ratio is 17.34. In terms of profitability, TLSI's ROE is +1.63%, compared to GMED's ROE of +0.13%. Regarding short-term risk, TLSI is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check GMED's competition here
Masimo Corporation (NASDAQ: MASI)
TLSI vs MASI Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas MASI's P/E ratio is 44.43. In terms of profitability, TLSI's ROE is +1.63%, compared to MASI's ROE of +0.09%. Regarding short-term risk, TLSI is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
TLSI vs GKOS Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, GKOS has a market cap of 9.2B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while GKOS trades at $156.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas GKOS's P/E ratio is -182.44. In terms of profitability, TLSI's ROE is +1.63%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, TLSI is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKR)
TLSI vs BRKR Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BRKR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BRKR's P/E ratio is 31.99. In terms of profitability, TLSI's ROE is +1.63%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, TLSI is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check BRKR's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
TLSI vs BIO-B Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BIO-B has a market cap of 8.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BIO-B trades at $324.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BIO-B's P/E ratio is 96.41. In terms of profitability, TLSI's ROE is +1.63%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, TLSI is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
TLSI vs BIO Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BIO trades at $304.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BIO's P/E ratio is 32.81. In terms of profitability, TLSI's ROE is +1.63%, compared to BIO's ROE of +0.02%. Regarding short-term risk, TLSI is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check BIO's competition here
Inari Medical, Inc. (NASDAQ: NARI)
TLSI vs NARI Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas NARI's P/E ratio is -59.24. In terms of profitability, TLSI's ROE is +1.63%, compared to NARI's ROE of -0.00%. Regarding short-term risk, TLSI is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
TLSI vs LIVN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while LIVN trades at $80.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas LIVN's P/E ratio is 20.18. In terms of profitability, TLSI's ROE is +1.63%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, TLSI is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
TLSI vs IRTC Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while IRTC trades at $110.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas IRTC's P/E ratio is -205.98. In terms of profitability, TLSI's ROE is +1.63%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, TLSI is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
TLSI vs AXNX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas AXNX's P/E ratio is -709.80. In terms of profitability, TLSI's ROE is +1.63%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, TLSI is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check AXNX's competition here
Integer Holdings Corporation (NYSE: ITGR)
TLSI vs ITGR Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ITGR has a market cap of 3.4B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ITGR trades at $95.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ITGR's P/E ratio is 15.81. In terms of profitability, TLSI's ROE is +1.63%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, TLSI is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check ITGR's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
TLSI vs ESTA Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ESTA has a market cap of 2.7B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ESTA trades at $92.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ESTA's P/E ratio is -64.29. In terms of profitability, TLSI's ROE is +1.63%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, TLSI is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ESTA's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
TLSI vs TMDX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while TMDX trades at $73.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas TMDX's P/E ratio is 30.20. In terms of profitability, TLSI's ROE is +1.63%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, TLSI is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
TLSI vs AXGN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while AXGN trades at $39.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas AXGN's P/E ratio is 104.87. In terms of profitability, TLSI's ROE is +1.63%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, TLSI is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check AXGN's competition here
NuVasive, Inc. (NASDAQ: NUVA)
TLSI vs NUVA Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas NUVA's P/E ratio is 75.00. In terms of profitability, TLSI's ROE is +1.63%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, TLSI is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check NUVA's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
TLSI vs UFPT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while UFPT trades at $242.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas UFPT's P/E ratio is 25.21. In terms of profitability, TLSI's ROE is +1.63%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, TLSI is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check UFPT's competition here
Novocure Ltd (NASDAQ: NVCR)
TLSI vs NVCR Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while NVCR trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas NVCR's P/E ratio is -10.41. In terms of profitability, TLSI's ROE is +1.63%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, TLSI is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check NVCR's competition here
Butterfly Network, Inc. (NYSE: BFLY)
TLSI vs BFLY Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BFLY trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BFLY's P/E ratio is -27.54. In terms of profitability, TLSI's ROE is +1.63%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, TLSI is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check BFLY's competition here
Enovis Corporation (NYSE: ENOV)
TLSI vs ENOV Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ENOV trades at $27.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ENOV's P/E ratio is 8.01. In terms of profitability, TLSI's ROE is +1.63%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, TLSI is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
TLSI vs IART Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while IART trades at $19.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas IART's P/E ratio is 8.41. In terms of profitability, TLSI's ROE is +1.63%, compared to IART's ROE of -0.48%. Regarding short-term risk, TLSI is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check IART's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
TLSI vs AHCO Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while AHCO trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas AHCO's P/E ratio is 24.91. In terms of profitability, TLSI's ROE is +1.63%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, TLSI is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check AHCO's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
TLSI vs INSP Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while INSP trades at $50.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas INSP's P/E ratio is 19.97. In terms of profitability, TLSI's ROE is +1.63%, compared to INSP's ROE of +0.18%. Regarding short-term risk, TLSI is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check INSP's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
TLSI vs ATEC Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ATEC trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ATEC's P/E ratio is -77.59. In terms of profitability, TLSI's ROE is +1.63%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, TLSI is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check ATEC's competition here
Heska Corporation (NASDAQ: HSKA)
TLSI vs HSKA Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas HSKA's P/E ratio is -62.49. In terms of profitability, TLSI's ROE is +1.63%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, TLSI is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check HSKA's competition here
CONMED Corporation (NYSE: CNMD)
TLSI vs CNMD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CNMD has a market cap of 1.3B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CNMD trades at $43.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CNMD's P/E ratio is 9.51. In terms of profitability, TLSI's ROE is +1.63%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, TLSI is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check CNMD's competition here
IRadimed Corporation (NASDAQ: IRMD)
TLSI vs IRMD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while IRMD trades at $97.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas IRMD's P/E ratio is 49.13. In terms of profitability, TLSI's ROE is +1.63%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, TLSI is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check IRMD's competition here
Artivion, Inc. (NYSE: AORT)
TLSI vs AORT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while AORT trades at $25.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas AORT's P/E ratio is 38.51. In terms of profitability, TLSI's ROE is +1.63%, compared to AORT's ROE of +0.03%. Regarding short-term risk, TLSI is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check AORT's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
TLSI vs TNDM Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while TNDM trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas TNDM's P/E ratio is -15.53. In terms of profitability, TLSI's ROE is +1.63%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, TLSI is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
TLSI vs AVNS Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while AVNS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas AVNS's P/E ratio is 27.76. In terms of profitability, TLSI's ROE is +1.63%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, TLSI is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check AVNS's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
TLSI vs SILK Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SILK's P/E ratio is -18.96. In terms of profitability, TLSI's ROE is +1.63%, compared to SILK's ROE of -0.35%. Regarding short-term risk, TLSI is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
TLSI vs FNA Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas FNA's P/E ratio is -19.83. In terms of profitability, TLSI's ROE is +1.63%, compared to FNA's ROE of -0.35%. Regarding short-term risk, TLSI is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
TLSI vs PRCT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while PRCT trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas PRCT's P/E ratio is -10.56. In terms of profitability, TLSI's ROE is +1.63%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, TLSI is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
TLSI vs LMRI Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while LMRI trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas LMRI's P/E ratio is -21.67. In terms of profitability, TLSI's ROE is +1.63%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, TLSI is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check LMRI's competition here
InMode Ltd. (NASDAQ: INMD)
TLSI vs INMD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, INMD has a market cap of 896.4M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while INMD trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas INMD's P/E ratio is 10.00. In terms of profitability, TLSI's ROE is +1.63%, compared to INMD's ROE of +0.13%. Regarding short-term risk, TLSI is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
TLSI vs CSII Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CSII's P/E ratio is -20.83. In terms of profitability, TLSI's ROE is +1.63%, compared to CSII's ROE of -0.14%. Regarding short-term risk, TLSI is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check CSII's competition here
Bioventus Inc. (NASDAQ: BVS)
TLSI vs BVS Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BVS has a market cap of 817M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BVS trades at $12.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BVS's P/E ratio is 16.08. In terms of profitability, TLSI's ROE is +1.63%, compared to BVS's ROE of +0.16%. Regarding short-term risk, TLSI is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
TLSI vs SIBN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SIBN has a market cap of 770.8M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SIBN trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SIBN's P/E ratio is -44.56. In terms of profitability, TLSI's ROE is +1.63%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, TLSI is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check SIBN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
TLSI vs SSII Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SSII has a market cap of 742.5M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SSII trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SSII's P/E ratio is -72.36. In terms of profitability, TLSI's ROE is +1.63%, compared to SSII's ROE of -0.23%. Regarding short-term risk, TLSI is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check SSII's competition here
CeriBell, Inc. (NASDAQ: CBLL)
TLSI vs CBLL Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CBLL has a market cap of 710.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CBLL trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CBLL's P/E ratio is -11.48. In terms of profitability, TLSI's ROE is +1.63%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, TLSI is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check CBLL's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
TLSI vs TCMD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, TCMD has a market cap of 648.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while TCMD trades at $28.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas TCMD's P/E ratio is 32.66. In terms of profitability, TLSI's ROE is +1.63%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, TLSI is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
TLSI vs CERS Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CERS has a market cap of 627.2M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CERS trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CERS's P/E ratio is -62.48. In terms of profitability, TLSI's ROE is +1.63%, compared to CERS's ROE of -0.15%. Regarding short-term risk, TLSI is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check CERS's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
TLSI vs BWAY Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BWAY has a market cap of 617M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BWAY trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BWAY's P/E ratio is 39.96. In terms of profitability, TLSI's ROE is +1.63%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, TLSI is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check BWAY's competition here
Surmodics, Inc. (NASDAQ: SRDX)
TLSI vs SRDX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SRDX's P/E ratio is -34.66. In terms of profitability, TLSI's ROE is +1.63%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, TLSI is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
TLSI vs CTKB Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CTKB has a market cap of 596.6M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CTKB trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CTKB's P/E ratio is -35.54. In terms of profitability, TLSI's ROE is +1.63%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, TLSI is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check CTKB's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
TLSI vs APEN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas APEN's P/E ratio is -9.43. In terms of profitability, TLSI's ROE is +1.63%, compared to APEN's ROE of -0.85%. Regarding short-term risk, TLSI is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check APEN's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
TLSI vs NPCE Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, NPCE has a market cap of 548.2M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while NPCE trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas NPCE's P/E ratio is -27.72. In terms of profitability, TLSI's ROE is +1.63%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, TLSI is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check NPCE's competition here
ZimVie Inc. (NASDAQ: ZIMV)
TLSI vs ZIMV Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, TLSI's ROE is +1.63%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, TLSI is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ZIMV's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
TLSI vs KIDS Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, KIDS has a market cap of 493.5M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while KIDS trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas KIDS's P/E ratio is -18.66. In terms of profitability, TLSI's ROE is +1.63%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, TLSI is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check KIDS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
TLSI vs OFIX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, OFIX has a market cap of 468.1M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while OFIX trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas OFIX's P/E ratio is -47.17. In terms of profitability, TLSI's ROE is +1.63%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, TLSI is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
TLSI vs CLPT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CLPT has a market cap of 454.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CLPT trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CLPT's P/E ratio is -15.00. In terms of profitability, TLSI's ROE is +1.63%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, TLSI is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check CLPT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
TLSI vs PACB Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, PACB has a market cap of 447.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while PACB trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas PACB's P/E ratio is -2.94. In terms of profitability, TLSI's ROE is +1.63%, compared to PACB's ROE of -4.88%. Regarding short-term risk, TLSI is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check PACB's competition here
Varex Imaging Corporation (NASDAQ: VREX)
TLSI vs VREX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, VREX has a market cap of 444.2M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while VREX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas VREX's P/E ratio is 11.11. In terms of profitability, TLSI's ROE is +1.63%, compared to VREX's ROE of -0.18%. Regarding short-term risk, TLSI is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check VREX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
TLSI vs DCTH Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, DCTH has a market cap of 442.2M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while DCTH trades at $12.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas DCTH's P/E ratio is 1281.00. In terms of profitability, TLSI's ROE is +1.63%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, TLSI is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check DCTH's competition here
Electromed, Inc. (AMEX: ELMD)
TLSI vs ELMD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ELMD has a market cap of 348.8M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ELMD trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ELMD's P/E ratio is 36.00. In terms of profitability, TLSI's ROE is +1.63%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, TLSI is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ELMD's competition here
Carlsmed, Inc. (NASDAQ: CARL)
TLSI vs CARL Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CARL has a market cap of 317M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CARL trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CARL's P/E ratio is -4.65. In terms of profitability, TLSI's ROE is +1.63%, compared to CARL's ROE of -0.62%. Regarding short-term risk, TLSI is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check CARL's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
TLSI vs AVR Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, AVR has a market cap of 310.9M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while AVR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas AVR's P/E ratio is -3.79. In terms of profitability, TLSI's ROE is +1.63%, compared to AVR's ROE of -1.24%. Regarding short-term risk, TLSI is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check AVR's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
TLSI vs SMLR Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SMLR's P/E ratio is 3.92. In terms of profitability, TLSI's ROE is +1.63%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, TLSI is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
TLSI vs TMCI Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, TMCI has a market cap of 279M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while TMCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas TMCI's P/E ratio is -4.57. In terms of profitability, TLSI's ROE is +1.63%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, TLSI is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check TMCI's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
TLSI vs SGHT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SGHT has a market cap of 273.7M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SGHT trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SGHT's P/E ratio is -7.08. In terms of profitability, TLSI's ROE is +1.63%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, TLSI is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check SGHT's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
TLSI vs MGRM Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas MGRM's P/E ratio is -12.00. In terms of profitability, TLSI's ROE is +1.63%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, TLSI is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check MGRM's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
TLSI vs CATX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CATX has a market cap of 230.7M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CATX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CATX's P/E ratio is -2.12. In terms of profitability, TLSI's ROE is +1.63%, compared to CATX's ROE of -0.42%. Regarding short-term risk, TLSI is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check CATX's competition here
RxSight, Inc. (NASDAQ: RXST)
TLSI vs RXST Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, RXST has a market cap of 229.8M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while RXST trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas RXST's P/E ratio is -7.71. In terms of profitability, TLSI's ROE is +1.63%, compared to RXST's ROE of -0.17%. Regarding short-term risk, TLSI is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check RXST's competition here
Nevro Corp. (NYSE: NVRO)
TLSI vs NVRO Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas NVRO's P/E ratio is -1.91. In terms of profitability, TLSI's ROE is +1.63%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, TLSI is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check NVRO's competition here
Picard Medical, Inc. (AMEX: PMI)
TLSI vs PMI Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, PMI has a market cap of 220.4M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while PMI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas PMI's P/E ratio is -0.12. In terms of profitability, TLSI's ROE is +1.63%, compared to PMI's ROE of +4.99%. Regarding short-term risk, TLSI is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check PMI's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
TLSI vs SENS Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, SENS has a market cap of 213.6M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while SENS trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas SENS's P/E ratio is -2.56. In terms of profitability, TLSI's ROE is +1.63%, compared to SENS's ROE of -1.30%. Regarding short-term risk, TLSI is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check SENS's competition here
Profound Medical Corp. (NASDAQ: PROF)
TLSI vs PROF Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, PROF has a market cap of 207.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while PROF trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas PROF's P/E ratio is -5.52. In terms of profitability, TLSI's ROE is +1.63%, compared to PROF's ROE of -0.70%. Regarding short-term risk, TLSI is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check PROF's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
TLSI vs FOCL Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, FOCL has a market cap of 203.7M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while FOCL trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas FOCL's P/E ratio is -6.99. In terms of profitability, TLSI's ROE is +1.63%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, TLSI is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check FOCL's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
TLSI vs ANIK Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ANIK has a market cap of 202.9M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ANIK trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ANIK's P/E ratio is 31.12. In terms of profitability, TLSI's ROE is +1.63%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, TLSI is more volatile compared to ANIK. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ANIK's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
TLSI vs BSGM Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas BSGM's P/E ratio is -5.81. In terms of profitability, TLSI's ROE is +1.63%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, TLSI is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check BSGM's competition here
Quanterix Corporation (NASDAQ: QTRX)
TLSI vs QTRX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, QTRX has a market cap of 182.1M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while QTRX trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas QTRX's P/E ratio is -2.42. In terms of profitability, TLSI's ROE is +1.63%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, TLSI is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
TLSI vs INGN Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, INGN has a market cap of 180.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while INGN trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas INGN's P/E ratio is -7.32. In terms of profitability, TLSI's ROE is +1.63%, compared to INGN's ROE of -0.13%. Regarding short-term risk, TLSI is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check INGN's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
TLSI vs MDGS Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas MDGS's P/E ratio is -0.27. In terms of profitability, TLSI's ROE is +1.63%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, TLSI is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
TLSI vs QIPT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas QIPT's P/E ratio is -15.87. In terms of profitability, TLSI's ROE is +1.63%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, TLSI is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check QIPT's competition here
CVRx, Inc. (NASDAQ: CVRX)
TLSI vs CVRX Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, CVRX has a market cap of 130.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while CVRX trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas CVRX's P/E ratio is -2.43. In terms of profitability, TLSI's ROE is +1.63%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, TLSI is less volatile compared to CVRX. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check CVRX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
TLSI vs RCEL Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, RCEL has a market cap of 126.7M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while RCEL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas RCEL's P/E ratio is -3.25. In terms of profitability, TLSI's ROE is +1.63%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, TLSI is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check RCEL's competition here
iCAD, Inc. (NASDAQ: ICAD)
TLSI vs ICAD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ICAD's P/E ratio is -20.37. In terms of profitability, TLSI's ROE is +1.63%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, TLSI is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
TLSI vs OWLT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, OWLT has a market cap of 101.1M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while OWLT trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas OWLT's P/E ratio is -39.93. In terms of profitability, TLSI's ROE is +1.63%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, TLSI is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check OWLT's competition here
Solana Company (NASDAQ: HSDT)
TLSI vs HSDT Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, HSDT has a market cap of 99.8M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while HSDT trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas HSDT's P/E ratio is -0.02. In terms of profitability, TLSI's ROE is +1.63%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, TLSI is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
TLSI vs HJLI Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas HJLI's P/E ratio is N/A. In terms of profitability, TLSI's ROE is +1.63%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, TLSI is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check HJLI's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
TLSI vs LUCD Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, LUCD has a market cap of 97.2M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while LUCD trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas LUCD's P/E ratio is -2.57. In terms of profitability, TLSI's ROE is +1.63%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, TLSI is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check LUCD's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
TLSI vs ASXC Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas ASXC's P/E ratio is -1.12. In terms of profitability, TLSI's ROE is +1.63%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, TLSI is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for TLSI.Check ASXC's competition here
Rapid Micro Biosystems, Inc. (NASDAQ: RPID)
TLSI vs RPID Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, RPID has a market cap of 93.8M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while RPID trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas RPID's P/E ratio is -1.85. In terms of profitability, TLSI's ROE is +1.63%, compared to RPID's ROE of -1.32%. Regarding short-term risk, TLSI is similarly volatile compared to RPID. This indicates similar risk in terms of short-term price fluctuations for TLSI.Check RPID's competition here
QT Imaging Holdings, Inc. (NASDAQ: QTI)
TLSI vs QTI Comparison July 2026
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLSI stands at 162.6M. In comparison, QTI has a market cap of 89M. Regarding current trading prices, TLSI is priced at $4.29 on the NASDAQ, while QTI trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLSI currently has a P/E ratio of -2.55, whereas QTI's P/E ratio is -4.82. In terms of profitability, TLSI's ROE is +1.63%, compared to QTI's ROE of -63.31%. Regarding short-term risk, TLSI is less volatile compared to QTI. This indicates lower risk in terms of short-term price fluctuations for TLSI.Check QTI's competition here